Protalix BioTherapeutics to Release Q3 2024 Results on Nov 14, 2024

Protalix BioTherapeutics, Inc., a company based in Carmiel, Israel, and listed on the NYSE American under the ticker symbol PLX, is a biopharmaceutical firm specializing in the development, production, and commercialization of recombinant therapeutic proteins. These proteins are produced using the company's proprietary ProCellEx® plant cell–based protein expression system. On November 7, 2024, Protalix BioTherapeutics announced that it would release its financial results for the quarter ending September 30, 2024. Additionally, the company plans to provide updates on its business and clinical developments on November 14, 2024.

The management team of Protalix BioTherapeutics will host a conference call on November 14, 2024, at 8:30 a.m. Eastern Standard Time (EST) to discuss the financial outcomes and recent corporate and regulatory updates. The conference call details are as follows: participants in the United States can join toll-free by dialing 1-877-423-9813, while international participants can dial 1-201-689-8573. Israeli participants can dial toll-free at 1-809-406-247. The conference ID for the call is 13749493.

To make the process smoother, participants can use the Call me™ feature, which allows them to enter their phone number on the platform, and the system will call them immediately, avoiding any wait time. Protalix has also made provisions for a webcast of the conference call. Participants are encouraged to log into the call at least 15 minutes early to register and download any necessary audio software. The webcast will be available on the Events Calendar in the Investors section of the company’s website, with a replay accessible for two weeks.

Protalix BioTherapeutics is recognized for its innovative approach to creating recombinant therapeutic proteins using its ProCellEx® plant cell-based expression system. This method has enabled the company to achieve significant milestones, including being the first to receive U.S. Food and Drug Administration (FDA) approval for a protein produced through plant cell-based suspension expression. This accomplishment marks a pivotal development in the industrial-scale production of recombinant proteins.

The company has forged a strategic partnership with Pfizer Inc. for the global development and commercialization of taliglucerase alfa, a treatment for Gaucher disease, which was Protalix's inaugural product utilizing the ProCellEx system. This collaboration excludes the Brazilian market, where Protalix retains exclusive rights. Another notable product from Protalix is Elfabrio®, which received approval from both the FDA and the European Medicines Agency in May 2023. Protalix is collaborating with Chiesi Farmaceutici S.p.A. for the worldwide development and commercialization of Elfabrio.

Protalix BioTherapeutics continues to advance its development pipeline, which includes proprietary recombinant therapeutic proteins targeting established pharmaceutical markets. Among the promising product candidates are PRX–115, a plant cell-expressed recombinant PEGylated uricase being developed for the treatment of uncontrolled gout, and PRX–119, a plant cell-expressed long-acting DNase I aimed at treating NETs-related diseases.

Protalix BioTherapeutics remains committed to leveraging its ProCellEx platform to create innovative treatments that address unmet medical needs. The upcoming financial results release and business update will provide further insights into the company's progress and future directions.